Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för solabegron. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

9 träffar

Bibliografisk träff 2016-03-21

Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.

Michel MC, Gravas S.

Expert Opin Drug Saf · review; journal article · DOI 10.1517/14740338.2016.1160055

Bibliografisk träff 2015-02-24

Synthesis of the β3-adrenergic receptor agonist solabegron and analogous N-(2-ethylamino)-β-amino alcohols from O-acylated cyanohydrins - expanding the scope of minor enantiomer recycling.

Hertzberg R, Monreal Santiago G, Moberg C.

J Org Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.joc.5b00322

Bibliografisk träff 2015-01-05

Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder.

Ellsworth P, Fantasia J.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2015.1001836

Bibliografisk träff 2012-06-05

A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.

Ohlstein EH, von Keitz A, Michel MC.

Eur Urol · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.eururo.2012.05.053

Bibliografisk träff 2009-09-25

The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin.

Schemann M, Hafsi N, Michel K, Kober OI, Wollmann J, Li Q, Zeller F, Langer R, Lee K, Cellek S.

Gastroenterology · research support, non-u.s. gov't; journal article · DOI 10.1053/j.gastro.2009.09.046

Bibliografisk träff 2008-03-27

Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health.

Grudell AB, Camilleri M, Jensen KL, Foxx-Orenstein AE, Burton DD, Ryks MD, Baxter KL, Cox DS, Dukes GE, Kelleher DL, Zinsmeister AR.

Am J Physiol Gastrointest Liver Physiol · research support, non-u.s. gov't; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1152/ajpgi.00051.2008

Bibliografisk träff 2007-07-12

GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.

Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, Luce TD, Coatney RW, Rivera GC, Westfall TD, Hieble JP.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.107.125757

Bibliografisk träff 2006-10-09

The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder.

Biers SM, Reynard JM, Brading AF.

BJU Int · journal article · DOI 10.1111/j.1464-410x.2006.06564.x

Bibliografisk träff 2006-05-01

Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.

Uehling DE, Shearer BG, Donaldson KH, Chao EY, Deaton DN, Adkison KK, Brown KK, Cariello NF, Faison WL, Lancaster ME, Lin J, Hart R, Milliken TO, Paulik MA, Sherman BW, Sugg EE, Cowan C.

J Med Chem · journal article · DOI 10.1021/jm0509445